FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
1. FDA approved Gilead's Yeztugo for HIV prevention, a breakthrough in treatment. 2. Yeztugo is expected to improve convenience over existing PrEP medications. 3. Potential threats include proposed funding cuts to HIV prevention by the GOP. 4. Gilead commits to broad access through insurance and programs for the uninsured. 5. Peak sales for lenacapavir projected at $4 billion globally for treatment and prevention.